Oncologie

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study 

Lancet Onco 2012 DOI:10.1016/S1470- 2045(12)70049-9 – Consulter l’abstract
Jean-Yves Pierga, Thierry Petit, Thierry Delozier, Jean-Marc Ferrero, Mario Campone, Joseph Gligorov, Florence Lerebours, Henri Roché, Thomas Bachelot, Emmanuelle Charafe-Jauffret, Maria Pavlyuk, Sandrine Kraemer, François-Clément Bidard, Patrice Viens

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

Use of Digital Health Technology to Enable Drug Development
Oncologie

Use of Digital Health Technology to Enable Drug Development

Primary efficacy analysis of a phase II study of neoadjuvant Bevacizumab, chemotherapy, and Trastuzumab in HER2-positive inflammatory breast cancer: BEVERLY 2 study
Oncologie

Primary efficacy analysis of a phase II study of neoadjuvant Bevacizumab, chemotherapy, and Trastuzumab in HER2-positive inflammatory breast cancer: BEVERLY 2 study

Surgical post-opérative complications in neoadjuvant treatment including Bevacizumab for HER2-positive inflammatory breast cancer: results from a phase II prospective trial
Oncologie

Surgical post-opérative complications in neoadjuvant treatment including Bevacizumab for HER2-positive inflammatory breast cancer: results from a phase II prospective trial